Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Grape King Bio's Sloan Ratio for the quarter that ended in Dec. 2024 was 1.53%.
As of Dec. 2024, Grape King Bio has a Sloan Ratio of 1.53%, indicating the company is in the safe zone and there is no funny business with accruals.
Grape King Bio Sloan Ratio % Historical Data
The historical data trend for Grape King Bio's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Grape King Bio's Sloan Ratio %
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Grape King Bio's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Grape King Bio's Sloan Ratio for the fiscal year that ended in Dec. 2024 is calculated as
Grape King Bio's Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was 257.881 (Mar. 2024 ) + 327.759 (Jun. 2024 ) + 415.887 (Sep. 2024 ) + 446.772 (Dec. 2024 ) = NT$1,448 Mil.
Grape King Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2024 was 113.221 (Mar. 2024 ) + 91.603 (Jun. 2024 ) + 460.967 (Sep. 2024 ) + 1210.121 (Dec. 2024 ) = NT$1,876 Mil.
Grape King Bio's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2024 was -96.52 (Mar. 2024 ) + -295.841 (Jun. 2024 ) + -127.89 (Sep. 2024 ) + -141.857 (Dec. 2024 ) = NT$-662 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grape King Bio (TPE:1707) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2024, Grape King Bio has a Sloan Ratio of 1.53%, indicating the company is in the safe zone and there is no funny business with accruals.
Grape King Bio Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Grape King Bio's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicine, liquid tonic, drink, and healthy food. The company has three segments: MLM (Multi-Level Marketing) is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TPE:1707 has been successfully added to your 